VIR_logo_large.jpg
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global...
VIR_logo_large.jpg
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
July 21, 2022 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...
VIR_logo_large.jpg
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
May 18, 2022 16:03 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20,...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 05, 2022 16:07 ET | Vir Biotechnology, Inc.
– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the...